

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4285511

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ANTIOP INC.	12/29/2016
RECEIVING PARTY DATA	
Name:	INDIVIOR, INC.
Street Address:	10710 MIDLOTHIAN TPKE
Internal Address:	STE 430
City:	RICHMOND
State/Country:	VIRGINIA
Postal Code:	23235
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	15005502
Patent Number:	9192570
Patent Number:	9289425
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617 542-6000
Email:	cdipasupil@mintz.com, IPDocketingBOS@mintz.com
Correspondent Name:	MINTZ LEVIN
Address Line 1:	ONE FINANCIAL CENTER
Address Line 4:	BOSTON, MASSACHUSETTS 02111
ATTORNEY DOCKET NUMBER:	48500-532
NAME OF SUBMITTER:	EDWARD D. GRIEFF
SIGNATURE:	/Edward D. Grieff/
DATE SIGNED:	02/22/2017
Total Attachments: 5	
source=48500-532_Assignment#page1.tif	
source=48500-532_Assignment#page2.tif	
source=48500-532_Assignment#page3.tif	

source=48500-532_Assignment#page4.tif

source=48500-532_Assignment#page5.tif

ASSIGNMENT AGREEMENT

This ASSIGNMENT AGREEMENT ("**Patent Assignment**") is effective as of December 29, 2016, and is given by AntiOp Inc., a Kentucky corporation ("**Assignor**").

WHEREAS Assignor is the owner of the inventions disclosed in the following patents:

U.S. Patent No. 9,192,570, entitled "Intranasal Naloxone Compositions and Methods of Making and Using Same," issued on November 24, 2015; **and**

U.S. Patent No. 9,289,425, entitled "Intranasal Naloxone Compositions and Methods of Making and Using Same," issued on March 22, 2016,

(collectively, the "**Patents**")

WHEREAS Assignor is the owner of the inventions disclosed in the following patent applications:

U.S.S.N. 61/918,802, entitled "Intranasal Naloxone Compositions and Methods of Making and Using Same," filed on 20 December 2013 (expired);

U.S.S.N. 14/576,357, entitled "Intranasal Naloxone Compositions and Methods of Making and Using Same," filed on December 19, 2014 (and issued as U.S. Patent No. 9,192,570);

U.S.S.N. 14/882,857 "Intranasal Naloxone Compositions and Methods of Making and Using Same," filed on October 14, 2015;

U.S.S.N. 15/005,502, entitled "Intranasal Naloxone Compositions and Methods of Making and Using Same," filed on January 25, 2016;

PCT/US14/71371, entitled "Intranasal Naloxone Compositions and Methods of Making and Using Same," filed on December 19, 2014;

EP 14 825 055.8, entitled "Intranasal Naloxone Compositions and Methods of Making and Using Same," filed on December 19, 2014;

CA 2,875,384, entitled "Intranasal Naloxone Compositions and Methods of Making and Using Same," filed on December 19, 2014; **and**

any and all related applications that may be filed,

(collectively, the "**Patent Applications**")

WHEREAS, ASSIGNOR has agreed to assign to Indivior, Inc. ("**ASSIGNEE**"), whose mailing address is 10710 Midlothian TPKE, STE 430, Richmond, VA 23235, the

entire right, title, and interest in and to the Patents and Patent Applications, and any patent(s) that may issue thereon;

AND WHEREAS, ASSIGNOR desires to memorialize the transfer to ASSIGNEE of the entire right, title, and interest in and to the Patents and Patent Application(s) and any patent(s) that may issue thereon.

NOW THEREFORE, for good and valuable consideration in the sum of one dollars (\$1.00), the receipt and sufficiency of which is hereby acknowledged, and pursuant to the requirements of (i) the Co-Development and Asset Purchase Agreement between Assignee and Assignor, executed on February 10, 2014; and (ii) the Mutual Release, Settlement, And Patent Assignment Agreement, effective as of December 29, 2016, ASSIGNORS do hereby sell, assign, transfer and convey to ASSIGNEE, its successors, assigns, and legal representatives the entire right, title, and interest in and to the said Patents and Patent Applications, including without limitation said Inventions, including in and to any provisional, conventional, design, division, continuation, continuation-in-part, substitution, reissue, renewal, reexam, continued prosecution application ("CPA"), or request for continued examination ("RCE") thereof, and in and to all inventions and improvements thereon (herein collectively referred to as "Related US Applications"), preparatory to obtaining Letters Patent of the United States therefor; and Assignor hereby requests the Commissioner of Patents and Trademarks to issue any and all Letters Patent of the United States resulting from said Applications and Related US Applications, to Assignee, for its interest and for the sole use and benefit of Assignee and its assigns and legal representatives.

For the same consideration, Assignor, does sell, assign, transfer and convey to Assignee all of Assignor's rights, title and interest in and to any foreign and international applications related to and/or seeking benefit of one or more said Patents, Patent Applications and Related US Applications, and in and to all inventions and improvements thereon (herein collectively referred to as "Related Foreign Applications"), in and to any Letters Patent and similar protective rights granted on said Related Foreign Applications, and in and to the right to claim any applicable priority rights arising from or required for said Related Foreign Applications under the terms of any applicable conventions, treaties, statutes, or regulations, said Related Foreign Applications to be filed and issued in the name of Assignee or its designee, insofar as permitted by applicable law.

For the same consideration, Assignor further agrees to reasonably assist and cooperate with Assignee and its successors and assigns in the prosecution and/or enforcement of the Patents and Patent Applications including, but not limited to, (i) testifying in any legal proceedings; (ii) signing all lawful papers; (iii) executing all divisional, continuation, continuation-in-part, reissues and substitute applications; and (iv) making all lawful declarations and oaths; provided however that Assignee will pay for any reasonable expenses incurred by Assignor in connection with providing such assistance.


AND, for the same consideration, Assignor also hereby sells, assigns and transfers unto Assignee all of Assignor's rights and claims to sue for damages and other remedies with respect to any and all past infringement of all said Patents, Patent Applications, Related US Applications, and Related Foreign Applications, including said inventions and improvements which may have occurred before the date of this Assignment.

IN WITNESS WHEREOF, we have hereunto set our hands and seals this 2nd
day of February, 2017.

ASSIGNOR:
ANTIOP INC.

By: *[Signature]*
Name: Daniel Wermeling
Title: CEO

Belinda L. Morgan
Notary Public



In WITNESS WHEREOF, Assignee hereby accepts from Assignor the sale, assignment, transfer and conveyance unto said Assignee of the full, exclusive and entire right, title, and interest in and to said Applications, by its duly authorized officer this 2nd day of FEBRUARY, 2017.

Indivior, Inc.
(Assignee)

By: Nancy DuVal

Name: NANCY DUVAL

Title: Authorized Signatory

18259430.1

County/City of CHESTERFIELD
Commonwealth/State of Virginia

The foregoing instrument was acknowledged before me this 2nd day of February 2017 by

Nancy DuVal
(name of person seeking acknowledgement)

Angela Denise Goodrich
Notary Public

My Commission Expires: 04-30-2018

